Inhibition of aldose reductase by dietary antioxidant curcumin: Mechanism of inhibition, specificity and significance

FEBS Letters

Volumn 583, Issue 22, 2009, Pages 3637-3642

  Muthenna, P ^a   Suryanarayana, P ^a   Gunda, Shravan K ^b   Petrash, J Mark ^c   Reddy, G Bhanuprakash ^a  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

^b OSMANIA UNIVERSITY   (India)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

AKR1B10; Aldo keto reductase; ALR2; Curcumin; Sorbitol

Indexed keywords

ALDEHYDE REDUCTASE; CURCUMIN; GLUCOSE; GLUCURONATE REDUCTASE; SORBITOL; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SPECIFICITY; ERYTHROCYTE; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; PRIORITY JOURNAL;

ALDEHYDE REDUCTASE; ANIMALS; ANTIOXIDANTS; CATTLE; CURCUMIN; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; GLUCOSE; HUMANS; ISOENZYMES; KIDNEY; KINETICS; MOLECULAR STRUCTURE; SORBITOL;

EID: 71749083155     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.10.042     Document Type: Article

References (33)

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
2. Kinoshita J.H. A thirty-year journey in the polyol pathway. Exp. Eye Res. 50 (1990) 567-573
3. Bhatnagar A., and Srivastava S.K. Aldose reductase: congenial and injurious profiles of an enigmatic enzyme. Biochem. Med. Metab. Biol. 48 (1992) 91-121
4. Kador P.F., Robison W.G., and Kinoshita J.H. The pharmacology of aldose reductase inhibitors. Annu. Rev. Pharmacol. Toxicol. 25 (1985) 691-714
5. Pfeifer M.A., Schumer M.P., and Gelber D.A. Aldose reductase inhibitors: the end of an era or the need for different trial designs?. Diabetes 46 (1997) S82-S89
6. Raskin P., and Rosenstock J. Aldose reductase inhibitors and diabetic complications. Am. J. Med. 83 (1987) 298-306
7. Jaspan J.B., Towle V.L., Maselli R., and Herold K. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Metabolism 35 (1986) 83-92
8. Foppiano M., and Lombardo G. Worldwide pharmacovigilance systems and tolrestat withdrawal. Lancet 349 (1997) 399-400
9. Srivastava S.K., Petrash J.M., Sadana I.J., Ansari N.H., and Partridge C.A. Susceptibility of aldehyde and aldose reductases of human tissues to aldose reductase inhibitors. Curr. Eye Res. 2 (1982) 407-410
10. Spite M., Baba S.P., Ahmed Y., Barski O.A., Nijhawan K., Petrash J.M., Bhatnagar A., and Srivastava S. Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes. Biochem. J. 405 (2007) 95-105
11. Hyndman D.J., and Flynn T.G. Sequence and expression levels in human tissues of a new member of the aldo-keto reductase family. Biochim. Biophys. Acta 1399 (1998) 198-202
12. Crosas B., Hyndman D.J., Gallego O., Martras S., Pare S.X., Flynn T.G., and Farre S.J. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem. J. 373 (2003) 973-979
13. Suryanarayana P., Kumar P.A., Saraswat M., Petrash J.M., and Reddy G.B. Inhibition of aldose reductase by tannoid principles of Emblica officinalis: implications for the prevention of sugar cataract. Mol. Vis. 10 (2004) 148-154
14. Suryanarayana P., Saraswat M., Mrudula T., Krishna T.P., Krishnaswamy K., and Reddy G.B. Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Invest. Ophthalmol. Vis. Sci. 46 (2005) 2092-2099
15. Suryanarayana P., Saraswat M., Petrash J.M., and Reddy G.B. Emblica officinalis and its enriched tannoids delay streptozotocin-induced diabetic cataract in rats. Mol. Vis. 24 (2007) 1291-1297
16. Mrudula T., Suryanarayana P., Srinivas P.N., and Reddy G.B. Effect of curcumin on hyperglycemia-induced vascular endothelial growth factor expression in streptozotocin-induced diabetic rat retina. Biochem. Biophys. Res. Commun. 21 (2007) 528-532
17. Saraswat M., Muthenna P., Suryanarayana P., Petrash J.M., and Reddy G.B. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications. Asia Pac. J. Clin. Nutr. 17 (2008) 58-65
18. Du Z.Y., Bao Y.D., Liu Z., Qiao W., Ma L., Huang Z.S., Gu L.Q., and Chan A.S. Curcumin analogs as potent aldose reductase inhibitors. Arch. Pharm. 339 (2006) 123-128
19. Petrash J.M., Harter T.M., Devine C.S., Olins P.O., Bhatnagar A., Liu S., and Srivastava S.K. Involvement of cysteine residues in catalysis and inhibition of human aldose reductase: site-directed mutagenesis of Cys-80, -298, and -303. J. Biol. Chem. 267 (1992) 24833-24840
20. Daly A.K., and Mantle T.J. Purification and characterization of the multiple forms of aldehyde reductase in ox kidney. Biochem. J. 205 (1982) 373-380
21. Malon J.I., Knox G., Benford S., and Tedesco T.A. Red cell sorbitol an indicator of diabetic control. Diabetes 29 (1980) 861-864
22. Bursulaya B.D., Totrov M., Abagyan R., and Brooks C.L. Comparative study of several algorithms for flexible ligand docking. J. Comput. Aided. Mol. Des. 11 (2003) 755-763
23. Stahl M., and Rarey M. Detailed analysis of scoring functions for virtual screening. J. Med. Chem. 44 (2001) 1035-1042
24. Engerman R.L., and Kern T.S. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes 42 (1993) 820-825
25. Oates P.J., and Mylari B.L. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin. Invest. Drugs 8 (1999) 2095-2119
26. Gallego O., Ruiz F.X., Ardevol A., Dominguez M., Alvarez R., Lera A.R., Rovira C., Farres J., Fita I., and Pares X. Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc. Natl. Acad. Sci. USA 52 (2007) 20764-20769
27. Ruiz F.X., Gallego O., Ardevol A., Moro A., Dominguez M., Alvarez S., Alvarez R., de Lera A.R., Rovira C., Fita I., Pares X., and Farres J. Inhibiting wild-type and C299S mutant AKR1B10: a homologue of aldose reductase upregulated in cancers. Chem. Biol. Interact. 178 (2008) 171-177
28. Bohren K.M., and Grimshaw C.E. The sorbinil trap: a predicted dead-end complex confirms the mechanism of aldose reductase inhibition. Biochemistry 39 (2000) 9967-9997
29. El-Kabbani O., Darmanin C., Schneider T.R., Hazemann I., Ruiz F., Oka M., Joachimiak A., Schulze B.C., Tomizaki T., Mitschler A., and Podjarny A. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors. Proteins 55 (2004) 805-813
30. Morrison A.D., Clements R.S., and Winegord A.I. Effects of elevated glucose concentration on the metabolism of the aorta wall. J. Clin. Invest. 51 (1972) 3114-3123
31. Reddy G.B., Satyanarayana A., Balakrishna N., Ayyagari R., Padma M., Viswanath K., and Petrash J.M. Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy. Mol. Vis. 14 (2008) 593-601
32. Kowluru R.A., and Kanwar M. Effects of curcumin on retinal oxidative stress and inflammation in diabetes. Nutr. Metab. (Lond.). 4 (2007) 8
33. Premanand C., Rema M., Sameer M.Z., Sujatha M., and Balasubramanyam M. Effect of curcumin on proliferation of human retinal endothelial cells under in vitro conditions. Invest. Ophthalmol. Vis. Sci. 47 (2006) 2179-2184